Evidence map›Paper›PMID 39219033›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2025

Diversity and Epitope Spreading of Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: A Potential Biomarker for Skin and Lung Involvement.

Hirohito Kotani, Kazuki M Matsuda, Kei Yamaguchi, Chihiro Ono, Emi Kogo, Koji Ogawa, Yuki Kobayashi, Teruyoshi Hisamoto, Ruriko Kawanabe, Ai Kuzumi and 5 more

Abstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hirohito KotaniUniversity of Tokyo, Bunkyo-ku, Japan.ORCID 0000-0003-1156-0663
Kazuki M MatsudaUniversity of Tokyo, Bunkyo-ku, Japan.ORCID 0000-0002-6755-8047
Kei YamaguchiProteoBridge Corporation, Koto-ku, Japan.
Chihiro OnoProteoBridge Corporation, Koto-ku, Japan.
Emi KogoProteoBridge Corporation, Koto-ku, Japan.
Koji OgawaProteoBridge Corporation, Koto-ku, Japan.
Yuki KobayashiProteoBridge Corporation, Koto-ku, Japan.
Teruyoshi HisamotoUniversity of Tokyo, Bunkyo-ku, Japan.
Ruriko KawanabeUniversity of Tokyo, Bunkyo-ku, Japan.
Ai KuzumiUniversity of Tokyo, Bunkyo-ku, Japan.ORCID 0000-0003-2261-7469
Takemichi FukasawaUniversity of Tokyo, Bunkyo-ku, Japan.ORCID 0000-0002-6093-1881
Asako Yoshizaki-OgawaUniversity of Tokyo, Bunkyo-ku, Japan.
Naoki GoshimaProteoBridge Corporation and the University of Musashino, Koto-ku, Japan.
Shinichi SatoUniversity of Tokyo, Bunkyo-ku, Japan.
Ayumi YoshizakiUniversity of Tokyo, Bunkyo-ku, Japan.ORCID 0000-0002-8194-9140

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEpitope spreading (ES), involving autoantibodies, plays a crucial role in the development and persistence of autoimmune reactions in various autoimmune diseases. This study aimed to investigate the relationship between ES of anti-RNA polymerase III (RNAP III) antibodies (ARAs) and the clinical manifestations of systemic sclerosis (SSc).

methodsWe investigated whether intermolecular ES occurs in the subunits of the RNAP III complex and whether intramolecular ES targets the major antigen, RNA polymerase III subunit A (RPC1), in patients with SSc. To achieve this, we synthesized 17 full-length subunit proteins of the RNAP III complex and 5 truncated forms of RPC1 in vitro using a wheat germ cell-free translation system. Subsequently, we prepared antigen-binding plates and measured autoantibodies in the serum of patients with SSc.

resultsAutoantibodies against different RNAP III complex subunits were found in patients who were ARA-positive with SSc. The intermolecular ES indicators significantly correlated with the modified Rodnan skin thickness score (mRSS) and surfactant protein-D, a biomarker of interstitial lung disease. However, the extent of disease on high-resolution computed tomography or pulmonary function tests did not show any significant correlation. Intramolecular ES indicator against RPC1 were significantly correlated with mRSS and renal crisis. Furthermore, longitudinal assessment of ES in RNAP III complex subunits correlated with mRSS and exhibited potential as a disease activity biomarker.

conclusionOur findings indicate a correlation between ES levels and the severity of skin sclerosis or the risk of other complications in SSc. This study suggests that measuring ES in SSc serves as a novel biomarker for disease activity.

Indexed as

AutoantibodiesBiomarkersEpitopesRNA Polymerase IIIScleroderma, SystemicAdultAgedFemaleHumansMaleMiddle AgedSkinAutoantibodiesBiomarkersEpitopesRNA Polymerase III

Identifiers

PMID39219033
PMCPMC11684998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.